Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.

Oncotarget - 20 Oct 2015

Li Yizhu, Saini Priyanka, Sriraman Anusha, Dobbelstein Matthias

Abstract excerpt

Pharmacological inhibition of the cell cycle regulatory kinase Wee1 represents a promising strategy to eliminate cancer cells. Wee1 inhibitors cooperate with chemotherapeutics, e. g. nucleoside analogues, pushing malignant cells from S phase towards premature mitosis and death. However, considerable toxicities are observed in preclinical and clinical trials. A high proportion of tumor cells can be distinguished...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspases
Share to Deoxycytidine
Share to Gemcitabine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HCT116 Cells

Share to Imidazoles

Share to Proto-Oncogene Proteins c-mdm2

Share to Pyrazoles

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 26431163
DOI: 10.18632/oncotarget.5891
PMCID: PMC4741697

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.PMID 26431163Read ↗

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.Semantic proximity Read ↗

Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging AgentsSemantic proximity Read ↗

Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer CellsSemantic proximity Read ↗

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cellsSemantic proximity Read ↗

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agentsSemantic proximity Read ↗

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)Semantic proximity Read ↗

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) AntagonistsSemantic proximity Read ↗

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.Semantic proximity Read ↗

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.Semantic proximity Read ↗

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.Semantic proximity Read ↗

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapySemantic proximity Read ↗

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.